Welcome to our dedicated page for Tevogen Bio news (Ticker: TVGNW), a resource for investors and traders seeking the latest updates and insights on Tevogen Bio stock.
Tevogen Bio Holdings Inc. (TVGNW) is a clinical-stage biotechnology company pioneering AI-driven precision T cell therapies for infectious diseases, cancers, and neurological disorders. This page serves as the definitive source for official company announcements, research breakthroughs, and strategic developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapeutic advancements, financial results, intellectual property updates, and leadership changes.
Key focus areas include Tevogen's innovative use of CD8+ cytotoxic T lymphocytes, developments in its Tevogen.AI platform, and strategic collaborations enhancing its immunotherapy pipeline. The news archive provides chronological tracking of the company's progress in creating accessible off-the-shelf treatments.
Bookmark this page for direct access to verified information about TVGNW's scientific advancements and corporate updates. Check regularly for new developments in precision immunotherapy and AI-enhanced drug discovery.
Tevogen Bio (Nasdaq: TVGN) is developing TVGN 920, a T cell therapy aimed at treating HPV in women with precancerous cervical lesions. This innovative treatment utilizes Tevogen's proprietary ExacTcell™ technology, employing genetically unmodified, allogeneic cytotoxic CD8+ CTLs targeting the HPV genome. The therapy's dual objectives are to prevent recurrent lesions that could lead to cervical cancer and eradicate HPV infection to halt virus transmission.
Key points:
- Approximately 1 in 3 women remain HPV positive after cervical procedures for precancerous lesions
- HPV is the primary risk factor for high-grade cervical lesion recurrence
- Tevogen aims to address this significant public health concern
- Success could pave the way for treatments of other virus-associated cancers
Tevogen Bio (Nasdaq: TVGN) highlights the publication of its phase I clinical trial data for TVGN 489, an investigational allogeneic SARS-CoV-2 specific CTL immunotherapy, in the journal Blood Advances. Key observations from the trial include:
- Faster symptom improvement and resolution in the treatment group compared to standard care
- Well-tolerated at all four doses tested
- High viral elimination rates (88%+ by day +4, >99% by day +14)
- No disease progression or Long COVID development in the treatment group
- Persistence of donor-derived CTLs through the 6-month follow-up period
The CEO, Ryan Saadi, expressed optimism about the company's ExacTcell™ platform, stating it represents a significant breakthrough in mainstreaming cell therapy through off-the-shelf T cell therapies for various applications.
Tevogen Bio (Nasdaq: TVGN), a clinical-stage biotech developing off-the-shelf T cell therapeutics, plans to update shareholders on its multi-billion dollar asset valuation following a recent $1b+ revenue potential announcement. CEO Ryan Saadi emphasizes the company's commitment to transparency and shareholder interests.
Key achievements include:
- Founding in 2020 and launch of proprietary ExacTcell technology
- 3 U.S. patents granted by 2022, with 9 pending and 12 international applications
- $4.2 billion valuation as highest valued biotech unicorn of 2022
- Positive proof-of-concept clinical trial results for TVGN 489 in 2023
- Introduction of Tevogen.AI and joining Microsoft for Startups program
- Public debut on Nasdaq in February 2024
- Inclusion in Russell 3000® Index
The company's pipeline includes treatments for SARS-CoV-2 infections, various cancers, and multiple sclerosis.
Tevogen Bio, a clinical-stage specialty immunotherapy biotech listed on Nasdaq (TVGN), plans to reveal its $1B+ revenue potential starting the week of October 14, 2024. The company develops off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers. CEO Ryan Saadi, a 2023 Nobel Nominee, emphasizes Tevogen's unique, faster, and cost-efficient drug development model as a potential blueprint for sustainable medical innovation.
Tevogen's pipeline includes:
- TVGN 489: For SARS-CoV-2 treatment in various patient groups and Long COVID
- TVGN 920: Cervical cancer prevention
- TVGN 930: EBV-associated lymphomas
- TVGN 960: Mouth and throat cancer
- TVGN 601: Multiple sclerosis
The company's approach aims to address pressing health conditions affecting large patient populations, reflecting strong business fundamentals and a patient-centric strategy.
Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, has announced updates to its therapeutic pipeline. The company is focusing on developing products for oncology and Long COVID using its ExacTcell™ technology platform. Tevogen aims to create therapies that not only treat cancer but also allow patients to maintain uninterrupted treatment.
The company is pursuing a prudent commercialization strategy, leveraging precision T cell therapies to address supportive care for cancer patients. Additionally, Tevogen is expanding its pipeline to include non-oncology products, adopting an opportunistic approach to maximize return on investment from its ExacTcell™ technology.
Tevogen Bio (Nasdaq: TVGN) has announced promising topline results from its Proof-of-Concept clinical trial for TVGN 489, an off-the-shelf T cell therapy for high-risk SARS-CoV-2 patients. The trial, conducted at Thomas Jefferson University Hospital, demonstrated:
- No dose-limiting toxicities or significant adverse events
- Reduction in viral load and presence of anti-COVID-19 responses
- All treated patients returned to baseline health within 14 days
- No COVID reinfection or Long COVID observed at 6-month follow-up
The treatment showed potential benefits for immunocompromised individuals and those at risk for severe COVID-19 outcomes. Tevogen Bio, valued at $4.2 billion in 2022, expects a substantial increase in its upcoming valuation report.
Tevogen Bio, a clinical-stage biotech company developing T cell therapeutics, recently met with U.S. Congress members to advocate for Long COVID patients and showcase their achievements. The company's CEO, Ryan Saadi, presented Tevogen's ExacTcell™ technology as a potential solution to the Long COVID crisis. Tevogen's lead product, TVGN 489, an off-the-shelf T cell therapeutic for acute SARS-CoV-2 infections, advanced from discovery to clinical phase within 18 months.
Key achievements include: founding in June 2020, obtaining 3 U.S. patents by 2022, being valued at $4.2 billion in 2022, announcing positive clinical trial results for TVGN 489 in 2023, introducing Tevogen.AI, and going public on Nasdaq in February 2024. The company's CFO, Kirti Desai, emphasized the significant market value of Tevogen's intellectual property assets, which include granted patents and pending applications in various countries.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has secured a $6 million Series C Preferred Stock investment from The Patel Family, LLP. The agreement includes:
- 7.5% annual dividend, accruing and payable quarterly
- Convertible to common stock after 6 months
- Callable by Tevogen after 5 years
- Non-voting and no mandatory redemption
- Dividends cease after 10 years if outstanding
The investment will be completed in two closings: $4 million on August 30, 2024, and $2 million on September 16, 2024. This long-term partnership reflects confidence in Tevogen's innovative approach to precision T cell therapies and its leadership team.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has reported its Q2 2024 financial results. Key highlights include:
- $5.1 million net cash used in operating activities for H1 2024
- $33.0 million in non-cash expenses, including $30.5 million in stock-based compensation
- $8.6 million in operating expenses for Q2 2024
- $2.4 million in current assets as of June 30, 2024
- $2.8 million received from Series A-1 Preferred Stock financing, with $3.0 million expected in Q3 2024
Tevogen has eliminated doubt about its ability to continue as a going concern, citing sufficient cash for at least 12 months of operations. The company also repurchased all outstanding Series B preferred shares at a fair value of $3.6 million, with no cash consideration.
Tevogen Bio (Nasdaq: TVGN) congratulates Professor Sten Vermund, Chairperson of its Innovation and Public Health Advisory Board, on his appointment as dean of the USF Health College of Public Health, effective January 1, 2025. Dr. Vermund will continue his role as President of the Global Virus Network (GVN), a nonprofit coalition of virologists from over 80 centers in 40 countries. The GVN focuses on combating future pandemic threats through research and development of drugs, vaccines, and treatments.
Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio, expressed pride in Dr. Vermund's appointment, highlighting his contributions to public health. Dr. Vermund cited exciting opportunities at USF, a public institution innovating at many levels, as a reason for his move from Yale School of Public Health.
